Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...

Shares of GSK Plc. were gaining around 6 percent on the London Stock Exchange, as well as in the pre-market activity on the NYSE, ...

GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.

British pharmaceutical group GSK on Wednesday reported a near halving of net profit in 2024 after settling hefty US lawsuits over its Zantac heartburn drug.

GSK (NYSE:GSK – Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 2.090-2.130 for the period, compared to the consensus earnings ...

GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...

GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.

London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.